DTIL Valuation

Precision BioSciences Inc

Add to Watchlist

Advanced Chart

5.130

-0.02(-0.388%)1D

Overview
Forecast
Valuation
Earnings

DTIL Relative Valuation

DTIL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DTIL is overvalued; if below, it's undervalued.

Historical Valuation

Precision BioSciences Inc (DTIL) is now in the Fair zone, suggesting that its current forward PS ratio of 3.25 is considered Fairly compared with the five-year average of -2.67. The fair price of Precision BioSciences Inc (DTIL) is between 3.92 to 6.05 according to relative valuation methord.

Relative Value

Fair Zone

3.92-6.05

Current Price：5.15

Fair

-0.61

Trailing

Forward

-0.18

EV/EBITDA

Precision BioSciences Inc. (DTIL) has a current EV/EBITDA of -0.18. The 5-year average EV/EBITDA is -0.84. The thresholds are as follows: Strongly Undervalued below -9.88, Undervalued between -9.88 and -5.36, Fairly Valued between 3.68 and -5.36, Overvalued between 3.68 and 8.21, and Strongly Overvalued above 8.21. The current Forward EV/EBITDA of -0.18 falls within the Historic Trend Line -Fairly Valued range.

-0.10

EV/EBIT

Precision BioSciences Inc. (DTIL) has a current EV/EBIT of -0.10. The 5-year average EV/EBIT is -1.03. The thresholds are as follows: Strongly Undervalued below -7.35, Undervalued between -7.35 and -4.19, Fairly Valued between 2.13 and -4.19, Overvalued between 2.13 and 5.29, and Strongly Overvalued above 5.29. The current Forward EV/EBIT of -0.10 falls within the Historic Trend Line -Fairly Valued range.

3.25

Precision BioSciences Inc. (DTIL) has a current PS of 3.25. The 5-year average PS is 7.38. The thresholds are as follows: Strongly Undervalued below -7.84, Undervalued between -7.84 and -0.23, Fairly Valued between 14.98 and -0.23, Overvalued between 14.98 and 22.59, and Strongly Overvalued above 22.59. The current Forward PS of 3.25 falls within the Historic Trend Line -Fairly Valued range.

-1.24

P/OCF

Precision BioSciences Inc. (DTIL) has a current P/OCF of -1.24. The 5-year average P/OCF is -5.71. The thresholds are as follows: Strongly Undervalued below -24.10, Undervalued between -24.10 and -14.91, Fairly Valued between 3.49 and -14.91, Overvalued between 3.49 and 12.69, and Strongly Overvalued above 12.69. The current Forward P/OCF of -1.24 falls within the Historic Trend Line -Fairly Valued range.

-67.20

P/FCF

Precision BioSciences Inc. (DTIL) has a current P/FCF of -67.20. The 5-year average P/FCF is -79.79. The thresholds are as follows: Strongly Undervalued below -721.32, Undervalued between -721.32 and -400.55, Fairly Valued between 240.97 and -400.55, Overvalued between 240.97 and 561.74, and Strongly Overvalued above 561.74. The current Forward P/FCF of -67.20 falls within the Historic Trend Line -Fairly Valued range.

Precision BioSciences Inc (DTIL) has a current Price-to-Book (P/B) ratio of 1.10. Compared to its 3-year average P/B ratio of 1.57 , the current P/B ratio is approximately -29.81% higher. Relative to its 5-year average P/B ratio of 3.47, the current P/B ratio is about -68.30% higher. Precision BioSciences Inc (DTIL) has a Forward Free Cash Flow (FCF) yield of approximately -105.96%. Compared to its 3-year average FCF yield of -101.31%, the current FCF yield is approximately 4.59% lower. Relative to its 5-year average FCF yield of -69.56% , the current FCF yield is about 52.33% lower.

1.10

P/B

Median3y

1.57

Median5y

3.47

-105.96

FCF Yield

Median3y

-101.31

Median5y

-69.56

Competitors Valuation Multiple

The average P/S ratio for DTIL's competitors is 305.06, providing a benchmark for relative valuation. Precision BioSciences Inc Corp (DTIL) exhibits a P/S ratio of 3.25, which is -98.93% above the industry average. Given its robust revenue growth of -99.84%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

DTIL.O

Precision BioSciences Inc

Gain Therapeutics Inc

Century Therapeutics Inc

Performance Decomposition

Market capitalization of DTIL decreased by 45.96% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from 0.00 to -1.85.

The secondary factor is the Revenue Growth, contributed -99.84%to the performance.

Overall, the performance of DTIL in the past 1 year is driven by P/E Change. Which is more unsustainable.

-99.84%

17.58M → 29.00K

Revenue Growth

-145296.13%

48.84 → -70.91K

Margin Expansion

145350.01%

0.00 → -1.85

P/E Change

-45.96%